By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Nuclea Technologies today announced a deal with Boston Medical Center for the discovery of new gene expression biomarkers to diagnose cancer.

Under the partnership, research will be directed at gene expression in specific tumors to help radiologists "review results in a different and more comprehensive way," Nuclea said in a statement.

Based in Pittsfield, Mass., Nuclea discovers and develops genetic, protein, and antibody biomarkers and diagnostic assays.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.